US Prenatal Testing Market Report: 2012 Edition
With the gradual evolution in the field of biomedical/healthcare technology, companies operating in the healthcare/pharmaceutical/therapeutic industry are now scaling new heights. Also, this industry is boosted by the rising number of incidences of health related issues emanating from the changing lifestyle and continuously changing surroundings.
To address the growing demand for better diagnosis and treatment options and the unmet needs within the chromosomal abnormalities and genetic disorders segment, respective companies are coming up with novel and improved diagnostics and testing methods. A part of the genetic testing segment includes the screening for genetic/chromosomal aberrations in the fetus termed as prenatal testing. By opting for the prenatal tests, birth defects like down syndrome, genetic disorders, cystic fibrosis, muscular dystrophy, spina bifida, thalassemia, among other chromosomal and genetic abnormalities could be detected before the birth of the child. The market is characterized by fast pace developments in the clinical technology and testing methodology.
The ongoing trends in the respective market include various strategic alliances, development of T21 testing assay by Sequenom, enhanced T21/T18 detection and reduced fetal loss by MaterniT21, ongoing clinical trials, and development of other fetal/maternal diagnostic tests. The drivers promoting prenatal testing market include factors like growth in genetic testing procedures, rising healthcare expenditure, increasing global GNI (gross national income), and increasing knowledge about genetic testing. Although it is a nascent development in the field of genetic testing, it has its own share of difficulties and hurdles where situations and elements such as adverse psychological impacts of prenatal testing, risks posed by invasive diagnostic procedures, escalating price pressure, and quality concerns related to biochemical genetic testing among others have been posing acute challenges.
This report provides a comprehensive overview of the US prenatal testing market covering the market opportunity for the T21 tests. The prenatal testing realm is getting intensely competitive with numerous corporations claiming the reins of the same. The leading industry players include PerkinElmer, Hologic and Sequenom among other global and domestic level players.
To address the growing demand for better diagnosis and treatment options and the unmet needs within the chromosomal abnormalities and genetic disorders segment, respective companies are coming up with novel and improved diagnostics and testing methods. A part of the genetic testing segment includes the screening for genetic/chromosomal aberrations in the fetus termed as prenatal testing. By opting for the prenatal tests, birth defects like down syndrome, genetic disorders, cystic fibrosis, muscular dystrophy, spina bifida, thalassemia, among other chromosomal and genetic abnormalities could be detected before the birth of the child. The market is characterized by fast pace developments in the clinical technology and testing methodology.
The ongoing trends in the respective market include various strategic alliances, development of T21 testing assay by Sequenom, enhanced T21/T18 detection and reduced fetal loss by MaterniT21, ongoing clinical trials, and development of other fetal/maternal diagnostic tests. The drivers promoting prenatal testing market include factors like growth in genetic testing procedures, rising healthcare expenditure, increasing global GNI (gross national income), and increasing knowledge about genetic testing. Although it is a nascent development in the field of genetic testing, it has its own share of difficulties and hurdles where situations and elements such as adverse psychological impacts of prenatal testing, risks posed by invasive diagnostic procedures, escalating price pressure, and quality concerns related to biochemical genetic testing among others have been posing acute challenges.
This report provides a comprehensive overview of the US prenatal testing market covering the market opportunity for the T21 tests. The prenatal testing realm is getting intensely competitive with numerous corporations claiming the reins of the same. The leading industry players include PerkinElmer, Hologic and Sequenom among other global and domestic level players.
1. PRENATAL TESTING
1.1 Overview
1.2 Types of Disorders Detected by Prenatal Tests
1.2.1 Down Syndrome
1.3 Prenatal Screening Techniques
1.4 Merits/Demerits of Genetic Testing
2. MARKET SIZE
2.1 Global Molecular Diagnostics Market
Molecular Diagnostics Market Value
Geographic Breakdown
Global Genetic Testing Market
2.2 Prenatal Testing Market Outlook
Trisomy 21 Test Market
Market Opportunity
T21 Test Volume Forecast
3. MARKET DYNAMICS
3.1 Key Trends and Industry Developments
3.1.1 Strategic Alliances
3.1.2 Development of T21 Testing Assay by Sequenom
3.1.3 Enhanced T21/T18 Detection and Reduced Fetal Loss by MaterniT21
3.1.4 Ongoing Clinical Trials
3.1.5 Development of Other Fetal/Maternal Diagnostic Tests
3.2 Growth Drivers
3.2.1 Growth in Genetic Testing Procedures
3.2.2 Rising Healthcare Expenditure
3.2.3 Increasing Global GNI (Gross National Income)
3.2.4 Increasing Knowledge about Genetic Testing
3.3 Challenges
3.3.1 Adverse Psychological Impacts of Prenatal Testing
3.3.2 Risks Posed by Invasive Diagnostic Procedures
3.3.3 Escalating Price Pressure
3.3.4 Quality Concerns Related to Biochemical Genetic Testing
4. COMPETITIVE LANDSCAPE
5. COMPANY PROFILES
5.1 PerkinElmer, Inc.
5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategies
Focus on Innovation
Growth via Strategic Acquisitions
5.2 Hologic, Inc.
5.2.1 Business Overview
5.2.2 Financial Overview
5.2.3 Business Strategies
Focus on Research & Development
Business Expansion via Strategic Acquisitions
5.3 Sequenom, Inc.
5.3.1 Business Overview
5.3.2 Financial Overview
5.3.3 Business Strategies
Development of Non-Invasive Prenatal Testing Protocol
Substantial Investment in R&D Activities
1.1 Overview
1.2 Types of Disorders Detected by Prenatal Tests
1.2.1 Down Syndrome
1.3 Prenatal Screening Techniques
1.4 Merits/Demerits of Genetic Testing
2. MARKET SIZE
2.1 Global Molecular Diagnostics Market
Molecular Diagnostics Market Value
Geographic Breakdown
Global Genetic Testing Market
2.2 Prenatal Testing Market Outlook
Trisomy 21 Test Market
Market Opportunity
T21 Test Volume Forecast
3. MARKET DYNAMICS
3.1 Key Trends and Industry Developments
3.1.1 Strategic Alliances
3.1.2 Development of T21 Testing Assay by Sequenom
3.1.3 Enhanced T21/T18 Detection and Reduced Fetal Loss by MaterniT21
3.1.4 Ongoing Clinical Trials
3.1.5 Development of Other Fetal/Maternal Diagnostic Tests
3.2 Growth Drivers
3.2.1 Growth in Genetic Testing Procedures
3.2.2 Rising Healthcare Expenditure
3.2.3 Increasing Global GNI (Gross National Income)
3.2.4 Increasing Knowledge about Genetic Testing
3.3 Challenges
3.3.1 Adverse Psychological Impacts of Prenatal Testing
3.3.2 Risks Posed by Invasive Diagnostic Procedures
3.3.3 Escalating Price Pressure
3.3.4 Quality Concerns Related to Biochemical Genetic Testing
4. COMPETITIVE LANDSCAPE
5. COMPANY PROFILES
5.1 PerkinElmer, Inc.
5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategies
Focus on Innovation
Growth via Strategic Acquisitions
5.2 Hologic, Inc.
5.2.1 Business Overview
5.2.2 Financial Overview
5.2.3 Business Strategies
Focus on Research & Development
Business Expansion via Strategic Acquisitions
5.3 Sequenom, Inc.
5.3.1 Business Overview
5.3.2 Financial Overview
5.3.3 Business Strategies
Development of Non-Invasive Prenatal Testing Protocol
Substantial Investment in R&D Activities
LIST OF CHARTS
Down’s Syndrome Incidence rate by Mother’s Age
FASTER Trial Down Syndrome Screening Results
Global Molecular Diagnostics Market (2005-2015E)
Global Molecular Diagnostic Market by Region (2010)
Global Genetic Testing Market (2007-2011)
Total Addressable Market Opportunity for the US (2012)
T21 Estimated Revenues (2012E & 2015E)
T21 tests Forecast —by Use (2012E-2015E)
T21 tests Forecast —by Patient Group (2012E-2015E)
Number of Genetic Tests and Laboratories Available Worldwide (1993-2011)
Global Healthcare Spending (2005-2015E)
World Gross National Income (2005-2010)
Worldwide Number of Diseases with Availability of Genetic Testing (2005-2011)
PerkinElmer’s Revenue Share by Segment (2012)
PerkinElmer’s Revenue and Net Income (2010-2012)
Hologic’s Revenue Share by Business Segment (2011)
Hologic’s Revenues and Net Income (2008-2011)
Sequenom’s Revenue Share by Business Segment (2011)
Sequenom’s Revenues and Net Income (2008-2011)
Down’s Syndrome Incidence rate by Mother’s Age
FASTER Trial Down Syndrome Screening Results
Global Molecular Diagnostics Market (2005-2015E)
Global Molecular Diagnostic Market by Region (2010)
Global Genetic Testing Market (2007-2011)
Total Addressable Market Opportunity for the US (2012)
T21 Estimated Revenues (2012E & 2015E)
T21 tests Forecast —by Use (2012E-2015E)
T21 tests Forecast —by Patient Group (2012E-2015E)
Number of Genetic Tests and Laboratories Available Worldwide (1993-2011)
Global Healthcare Spending (2005-2015E)
World Gross National Income (2005-2010)
Worldwide Number of Diseases with Availability of Genetic Testing (2005-2011)
PerkinElmer’s Revenue Share by Segment (2012)
PerkinElmer’s Revenue and Net Income (2010-2012)
Hologic’s Revenue Share by Business Segment (2011)
Hologic’s Revenues and Net Income (2008-2011)
Sequenom’s Revenue Share by Business Segment (2011)
Sequenom’s Revenues and Net Income (2008-2011)
LIST OF TABLES
Existing Noninvasive Prenatal Screening Options
Methods of Prenatal Testing
Prenatal Screening Techniques
Trisomy 21 Test Market Model for the US (2011-2016E)
Total Addressable Market Opportunity for the US (2012)
T21 Market Test Volume Forecast for the US (2012E-2015E)
Sequenom’s External and Related Party Relationships
Improvement in Down syndrome Detection & Fetal Loss from Inclusion of SQNM's MaterniT21 PLUS in Clinical Diagnostic Paradigm
Existing Noninvasive Prenatal Screening Options
Methods of Prenatal Testing
Prenatal Screening Techniques
Trisomy 21 Test Market Model for the US (2011-2016E)
Total Addressable Market Opportunity for the US (2012)
T21 Market Test Volume Forecast for the US (2012E-2015E)
Sequenom’s External and Related Party Relationships
Improvement in Down syndrome Detection & Fetal Loss from Inclusion of SQNM's MaterniT21 PLUS in Clinical Diagnostic Paradigm
